We remain invested in the project as well. @Dividendenopi
Citizens raises its price target for Mirum Pharmaceuticals from $144 to $167 and reaffirms its rating of“Market Outperform”. The new price target implies upside potential of approximately 92% compared to the aforementioned price level of $87.03. The analyst consensus remains at“Strong Buy”. [de.investing.com]
The main reason for the upgrade is the strong growth of the key product Livmarli , as well as an increasingly diversified pipeline with several advanced development programs. According to the data cited in the article, Mirum achieved revenue growth of 44% over the past twelve months, with a gross margin of 81.7%. [de.investing.com]
The Phase 3 EXPAND study met the primary endpoint and all key secondary endpoints. This supports a planned sNDA application in the first half of 2027 for additional rare cholestatic diseases, including biliary atresia. Management estimates revenue potential of $300 million to $400 million. [de.investing.com]
In addition, Atebrioz was launched for the treatment of FOP. Citizens estimates potential peak sales at approximately $200 million, which is in line with management’s expectations. [de.investing.com]
The analyst names Mirum as one of his favorites in the rare disease sector, as Livmarli is delivering reliable growth and the pipeline is becoming increasingly diversified. [de.investing.com]
The latest Q3 2026 results exceeded expectations in terms of revenue:
- Revenue: $185.7 million (Consensus: $178.06 million)
- EPS:-0.87 USD (weaker than the expected -$0.49)
- Nevertheless, the market reacted positively to the revised-up revenue forecast and the progress in the pipeline. [de.investing.com]
Juan’s take: 🧪
For growth investors, the story is clear right now: Livmarli is growing strongly, new indications could significantly expand the addressable market, and Atebrioz offers an additional source of revenue. The price target increase is based primarily on the expectation that Mirum will be able to successfully convert its pipeline into further revenue drivers. The greatest upside potential now hinges on regulatory successes in 2027 and the continued commercialization of treatments for rare diseases. [de.investing.com]
